Influenza A (H5N1) pandemic prototype vaccine Fluval.
The timely development of safe and effective vaccines is likely to be the single most important public-health tool for decreasing the morbidity, mortality and economic effects of the influenza pandemic. The objective of this article is to provide a detailed description of the chemistry and immunogenicity of one of the better studied inactivated whole-virion aluminum phosphate-adjuvanted vaccines, Fluval (Omninvest, Hungary), while we discuss safety data of all clinical trials published on H5N1 vaccines to date. Fluval was chosen for detailed discussion owing to its immunogenicity after only one dose, the fact that it was one of the very first H5N1 vaccines that demonstrated the potential for dose sparing and, unlike all mainstream oil-in-water adjuvanted reverse genetics-derived H5N1 vaccines, it is whole virion based.
Vajo
Zoltan
Z
University of Debrecen, Medical and Health Science Center, Debrecen, Hungary. zoltanvajo@gmail.com
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D017607:Aluminum Compounds / Q000494:pharmacology; D004196:Disease Outbreaks / Q000517:prevention & control; D006801:Humans; D006814:Hungary; D053124:Influenza A Virus, H5N1 Subtype / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control; D010710:Phosphates / Q000494:pharmacology; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D007252:Influenza Vaccines; D010710:Phosphates; D015164:Vaccines, Inactivated; C012714:aluminum phosphate